
Get exclusive money-saving offers and guides
Straight to your inbox
Updated
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Invex Therapeutics Ltd is a biotechnology business based in Australia. Invex Therapeutics shares (IXC) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. Invex Therapeutics has a trailing 12-month revenue of around $165,703..
Our top pick for
US stocks
Our top pick for
Cheap broker fees
Our top pick for
Long-term investing
52-week range | $0.53 - $1.58 |
---|---|
50-day moving average | $0.7559 |
200-day moving average | $0.9056 |
Target price | N/A |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-0.03 |
Standard brokerage - Australian shares
Competitive broker fees on Australian and international shares
Important: Share trading carries risk of capital loss.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the close of A$0.78 on 2021-01-25
1 week (2021-01-18) | -4.29% |
---|---|
1 month (2020-12-24) | 5.41% |
3 months (2020-10-24) | N/A |
6 months (2020-07-24) | -23.53% |
1 year (2020-01-24) | -22.00% |
---|---|
2 years (2019-01-24) | N/A |
3 years (2018-01-24) | N/A |
5 years (2016-01-24) | N/A |
Revenue TTM | $165,703 |
---|---|
Gross profit TTM | $165,703 |
Return on assets TTM | -10.47% |
Return on equity TTM | -18.75% |
Profit margin | 0% |
Book value | 0.362 |
Market capitalisation | $57.1 million |
TTM: trailing 12 months
We're not expecting Invex Therapeutics to pay a dividend over the next 12 months.
Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase II clinical trial. The company was incorporated in 2019 and is based in Subiaco, Australia.
Steps to owning and managing Vanguard Australian Fixed Interest Index ETF units.
Steps to owning and managing Vanguard Ethically Conscious Global Aggregate Bond Index (Hedged) ETF units.
Steps to owning and managing ETFS Morningstar Global Technology ETF units.
Steps to owning and managing BetaShares Global Quality Leaders (Currency Hedged) ETF units.
Steps to owning and managing ETFS ROBO Global Robotics and Automation ETF units.
Steps to owning and managing ETFS FANG+ ETF units.
Steps to owning and managing ETFS S&P Biotech ETF units.
Steps to owning and managing ETFS Reliance India Nifty 50 ETF units.
Steps to owning and managing BetaShares India Quality ETF units.